Nurix Therapeutics, Inc. 4

Nurix Therapeutics CFO Hans van Houte had multiple RSUs vest into common stock and sold 2,845 shares (~$66K) solely to cover taxes on July 30, 2026, leaving him with 44,927 shares plus significant unvested RSUs.

On July 30, 2026, Nurix Therapeutics, Inc. CFO Hans van Houte had multiple restricted stock unit (RSU) tranches vest and convert into common stock at no cost, with 3,750, 2,858, and 3,572 shares of common stock acquired from RSU vesting, increasing his directly held common stock to 47,772 shares before a concurrent tax-related sale. On the same date, 2,845 shares of common stock were sold at a weighted average price of $23.3828 per share (within a $23.00–$23.90 range) solely to satisfy tax withholding obligations under a mandatory sell‑to‑cover election, reducing his post‑sale direct holdings to 44,927 common shares. Corresponding RSU balances decreased as the units were settled into shares, leaving 11,250, 20,009, and 39,303 RSUs outstanding in three separate awards that continue to vest quarterly over three-year schedules. Using the disclosed sale price as a proxy, the tax sale was approximately $66,600 in value, and his remaining common stock holdings are worth roughly $1.05 million, with substantial additional value in unvested RSUs, making this filing largely a routine equity compensation vesting and tax‑withholding event rather than a discretionary open‑market trade.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

fda

Accession

0001817217-26-000010

Alert Tier

5